Sector Watch: Healthcare - Sep 28 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $121.94 +0.07 0.06% | XBI: $95.87 -0.12 -0.13% | Updated Sep 28, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| CRMD52WH CorMedix Inc $94.8M |
0.97+0.23 10.6 M 4.1x |
32% | ||
| AMRN52WH Amarin $5.4B |
16.27+2.44 37.0 M 2.5x |
18% | ||
| CCXI ChemoCentryx $636.8M |
12.64+1.83 1.7 M 7.3x |
17% | ||
| VBIV VBI Vaccines $135.9M |
2.42+0.31 520.9 K 2.7x |
15% | ||
| SNDX Syndax Pharmaceuticals $188.7M |
8.08+0.94 1.4 M 4.5x |
13% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| GERN Geron $323.2M |
1.76-0.55 44.5 M 3.7x |
-24% | ||
| CBMG Cellular Biomedicine Group $307.9M |
18.15-3.85 192.8 K 3.8x |
-18% | ||
| ADMP Adamis Pharmaceuticals $165.5M |
3.50-0.53 4.5 M 3.6x |
-13% | ||
| CASI CASI Pharmaceuticals $404.4M |
4.67-0.49 194.0 K |
-10% | ||
| VSAR Versartis $50.7M |
1.40-0.10 106.1 K |
-7% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock [globenewswire.com]CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer [prnewswire.com]
Thinking about buying stock in Advanced Micro Devices, BlackBerry Ltd, Geron Corporation, NVIDIA or Tesla? [prnewswire.com]
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product [globenewswire.com]
VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference [globenewswire.com]
Microscopic Polyangiitis (MPA) Pipeline Review, H2 2018 - Therapeutic Assessment of 5 Companies - ResearchAndMarkets.com | Business Wire [businesswire.com]
Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018 [globenewswire.com]
Amarin to Present at the Cantor Global Healthcare Conference Nasdaq:AMRN [globenewswire.com]
Janssen Elects Not to Continue Agreement with Geron for Imetelstat [prnewswire.com]
Sandoz Inc. announces US FDA approval of pediatric dose of SYMJEPI? (epinephrine) [prnewswire.com]
Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China [prnewswire.com]
Geron Corp. (GERN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws [prnewswire.com]
ChemoCentryx Announces Proposed Public Offering of Common Stock [globenewswire.com]
ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference [globenewswire.com]
VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards [globenewswire.com]
Syndax to Present at the 2018 Cantor Global Healthcare Conference [prnewswire.com]
Syndax Announces Changes to its Board of Directors [prnewswire.com]
Thinking about buying stock in Amarin Corporation, Facebook, General Electric, Netflix or Pandora? [prnewswire.com]
Cellular Biomedicine Group to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference [globenewswire.com]
REDUCE-IT? Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint [globenewswire.com]
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer [prnewswire.com]
Glomerulonephritis - Pipeline Review, H2 2018 - Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com | Business Wire [businesswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
